Home › Companies › TSHA

Taysha Gene Therapies

TSHA Rare disease Lead: Phase 3 7 Biotech Distilled articles ↓

Neurology Gene Therapy

Most recent annual filing: 2026-03-19

Pipeline (4 active programs)

TSHA-102

Gene Therapy Target: MECP2

Rett Syndrome Phase 3 Phase 1/2 trial intrathecal NCT05606614

TSHA-113

Gene Therapy Target: MAPT, tau

Undisclosed indication Preclinical

TSHA-114

Gene Therapy Target: FMR1, FMRP

Fragile X Syndrome Preclinical

TSHA-120

Gene Therapy Target: GAN

Giant Axonal Neuropathy

Discontinued (1)

TSHA-106 — Angelman Syndrome · discontinued evaluation of TSHA-106 in 2025

Biotech Distilled coverage (7)

2026-08-15 UPDATE: Taysha Gene Therapies (TSHA) - Follow the Money, Finally 🔒 Paid
2026-08-12 UPDATE: Taysha Gene Therapies (TSHA) - The First Asterisk on a Clean Safety Record 🔒 Paid
2026-08-03 UPDATE: Taysha Gene Therapies (TSHA) - The Factory Gets a Landlord 🔒 Paid
2026-06-25 UPDATE: Taysha Gene Therapies (TSHA) - The Deal Prints at $6.00 🔒 Paid
2026-06-24 UPDATE: Taysha Gene Therapies (TSHA) - The $200M Raise on Strength 🔒 Paid
2026-06-22 UPDATE: Taysha Gene Therapies (TSHA) - The Dimmer Switch Holds 🔒 Paid
2026-04-25 Taysha Gene Therapies (TSHA) - Scientific Deep Dive for TSHA-102 and Pipeline Products 🔒 Paid

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.